This event has been approved by the Faculty of Pharmaceutical Medicine with 1.5 CPD points
This promotional meeting sponsored by BeiGene brought together a group of clinical experts to discuss their experience of treating patients with Waldenstrom’s Macroglobulinaemia using BRUKINSA®▼ (zanubrutinib), a next generation BTK inhibitor. Sharing case studies and discussing the role of BRUKINSA® in treatment pathways and hospital protocols.
The second part of the meeting focused on the role of BRUKINSA® (zanubrutinib) in treating Chronic Lymphocytic Leukaemia (CLL).
We invite you to register to watch the on-demand content.
BRUKINSA® as monotherapy is indicated for the treatment of adult patients with Waldenström’s Macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
BRUKINSA® as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
BRUKINSA® as monotherapy is indicated for the treatment of adult patients with Chronic Lymphocytic Leukaemia (CLL).
Agenda:
For full PDF, please see here
This meeting is intended for UK and Ireland Healthcare Professionals only.
To access the BRUKINSA® (zanubrutinib) prescribing and adverse event reporting information, please see the BRUKINSA® Prescribing Information document.
Please refer to the SmPC for full information.1
Adverse events should be reported. |
References: 1. BRUKINSA® UK Summary of Product Characteristics.
Enter your email address to get started
Prof Follows is a former chair of the UK CLL Forum and CLL Guidelines Panel and Research Lead for haematology clinical trials at the Cambridge Cancer Trials Centre. He currently chairs the UK Hodgkin Lymphoma Guidelines Panel and is an Associate Professor affiliated to the University of Cambridge Department of Haematology.
Dr McKay is a Consultant Haematologist at the Beatson, West of Scotland Cancer Centre and an Honorary Clinical Associate Professor at the University of Glasgow School of Medicine. She has a specialist interest in lymphoma and is actively involved in lymphoma at a regional and national level. She is currently a member of the NCRI Lymphoma Clinical Studies Group and the high-grade lymphoma and Hodgkin's lymphoma Clinical Studies Subgroups.
Dr Toby Eyre is a consultant haematologist at Oxford University Hospitals NHS Foundation Trust specialising in the management of lymphoid malignancies. He is an expert in the management of patients with lymphoma and patients with chronic lymphocytic leukaemia. He was the BSH-NIHR Researcher of the year in 2021 and is an Associate Editor at the British Journal of Haematology.
Dr Lawless specialises in lymphoma, myeloma and haematopoietic stem cell transplantation. Dr Lawless began her career in haematology at BCH in 2008 and she currently holds the position of speciality improvement and SACT lead at Belfast City Hospital. She is actively involved in clinical trials and is a member of UK NCRI group and is the invited regional N. Ireland representative on the UK Myeloma Society executive committee.
After completing his medical education and postgraduate training in internal medicine from King Edward Memorial Hospital in Mumbai, India with 7 distinctions, Dr Jayakar did haematology SHO jobs at UCL and Royal Marsden, London whilst acquiring his MRCP qualification. He has been a Consultant Haematologist at Kingston Hospital, London since 2011. He also co-organises the venerable Imperial Morphology Courses with Prof Barbara Bain and has a honorary lecturer contract at Imperial College, London.
